Amp Volatility Score
Catalyst Info & Data Links
TITLE: Influenza Vaccine Phase 2/Janssen report readout
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 begins
Janssen Report Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Vaxart’s VAAST™ delivery platform employs a modular approach using a replication-incompetent adenovirus type 5 (Ad5) vector that delivers two payloads to the cells of the mucosal epithelium of the small bowel. One payload is the gene coding for the selected pathogen-specific protein antigen. The other payload, which is always co-delivered, is the gene coding for the Toll Like Receptor-3 (TLR-3) agonist, an adjuvant that activates the innate immune system, and was selected for its ability to stimulate broad immune responses. Every vaccine contains the TLR-3 adjuvant component.
Updated by MV
#VXRT #INFLUENZA #VAXART
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post